What’s more, the addition of brentuximab vedotin did not change the incidence and severity of adverse events such as febrile neutropenia (18% of patients in the A + CHP group and 15% in the CHOP group) and peripheral neuropathy (52% in the A + CHP group and 55% in the CHOP group). The gene discussed is DDIT3; the disease is peripheral neuropathy.